Research programme: endothelin B receptor antagonists - ENB Therapeutics

Drug Profile

Research programme: endothelin B receptor antagonists - ENB Therapeutics

Alternative Names: ENB 001; ENB 002; ETBR blocker - ENB Therapeutics

Latest Information Update: 01 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ENB Therapeutics
  • Class Small molecules
  • Mechanism of Action Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma; Head and neck cancer; Malignant melanoma

Most Recent Events

  • 25 Apr 2016 Preclinical trials in Glioblastoma in USA (SC)
  • 25 Apr 2016 Preclinical trials in Head and neck cancer in USA (SC)
  • 25 Apr 2016 ENB Therapeutics enters into a partnership with an undisclosed company for nanoparticle intranasal drug delivery system
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top